The Loyola Cardiology division has earned their reputation for offering a premier program in Chicago and one of the finest in the nation. Your care, whether simple or complex, is in the hands of seasoned experts trained in all types of heart and vascular care. The innovative track record of the division speaks for itself with proven patient outcomes and volumes.
The Cardiology Division offers the experience and expertise of many of the nation's top heart and vascular specialists in all areas of treatment. For a detailed list of Loyola's cardiac services, treatment offerings and locations, please visit Loyola Heart & Vascular Services web site.
We perform both cardiac and peripheral diagnostic and therapeutic/interventional procedures on adults and pediatric patients in our three state-of-the-art catheterization suites. Loyola's cardiologists offer a wide variety of procedure choices, many of which are not available at the typical community hospital. Loyola interventional cardiologists perform nearly 4,500 cardiac catheterizations annually, the most in northern Illinois.
Loyola's electrophysiology faculty are among the nation's leaders in the care of adults and children with heart rhythm disorders (arrhythmias).Services include diagnostic EP studies, cardioversions or application of electrical current (energy) to restore normal heartbeat, ablation procedures, and pacemaker and defibrillator implantation.
Loyola offers a contemporary approach to the diagnosis, prevention and treatment of peripheral vascular disease (PVD). A multidisciplinary team of doctors from interventional cardiology, radiology and vascular surgery care for patients with PVD.
As a major solid organ transplant center in the United States, Loyola has programs in heart, lung and heart-lung transplantation. Faculty provide aggressive medical management, the latest in medications and work closely with the Department of Thoracic and Cardiovascular Surgery to offer conventional and leading-edge surgery. One of the oldest and most active programs in the United States, with more than 600 transplants performed since March 1984.
George M. Eisenberg Professor of Cardiovascular Sciences
Director, Cardiovascular Institute
Division Director, Cardiology
The Division of Cardiology offers five fellowship programs. These programs are highly competitive and successfully prepare fellows for outstanding careers in Cardiology. The Cardiovascular institute also offers a Thoracic and Cardiovascular Surgery Training program. In addition, the division offers various Continuing Medical Education courses each year for fellow physicians.
- General cardiology
- Electrophysiology cardiology
- Interventional cardiology
- Advanced Cardiovascular Imaging
- Advanced Heart Failure and Transplant Cardiology
To schedule an appointment, please contact Loyola Central Scheduling at (708) 216-8563.
Loyola University Medical Center
2160 South First Avenue
Division of Cardiology
Building 110 - Room 6269
Maywood, IL 60153
Phone: (708) 327-3270
Fax: (708) 327-2377
Current Research Projects
|Research Project||Principal Investigator||Funding Source||Description|
|Developmental Alterations in Cardiac Protein Turnover||J Akar||Medtronic||To study the effect of BEEF in patients with congestive heart failure|
|Calcium Entry and Vascular Smooth Muscle Excitation||KL Byron
|NIH/NHLBI||To identify non-selective cation currents in arterial smooth muscle cells and determine their roles in vasopressin-induced action potential generation.|
|T-Type Ca Channels in Development and Cell Proliferation||L Cribbs||NIH/NHLBI||To understand the role of T-type Ca channels in the cardiovascular system with particular focus on instances where they appear to predominate and have unique functions over high voltage-activated, L-type channels.|
|Altered Mechanotransduction Signaling in Type 2 Diabetes and Diabetic Cardiomyopathy||A Goodman
|American Heart Association||To determine what mechanotransduction signaling molecules are differentially regulated in the heart as a result of diabetes and to look specifically at the regulation of PYK2 in the diabetic milieu|
|Antiplatelet Effect of PAR-1 Inhibitors||WP Jeske||Caden Biosciences||To determine whether a specific series of small molecules modulate platelet-activation response.|
|Novel Heparin Antagonists||WP Jeske
|PolyMedix||To create a comparative neutralization profile of unfractionated heparin by PolyMedix's novel site-directed antagonists|
|Beta-Adrenergic Receptor Function in Atrial Myocytes||SL Lipsius
|NIH/NHLBI||To test the hypothesis that the ECM-integrin-cytoskeletal complex remodels beta-adrenergic receptor function in atrial myocytes.|
|Serotonin Therapy for Parkinson's Disease and Neurodegenerative Disorders||J Martin||Hines VA Hospital||To develop and produce adeno-associated virus vector genetic constructs for the purpose of developing a novel model of progressive neuronal degeneration as seen in Parkinson's disease. (subcontract with Hines VA Hospital for which Dr. William Wolf is principal investigator)|
|Human Adult Bone Marrow-Derived Stem Cell Therapy for Recovery from Ischemic Stroke||J Martin||Illinois Department of Public Health||To develop and produce adeno-associated virus vector genetic constructs. (subcontract with Hines VA Hospital for which Dr. Gwendolyn Kartje is principal investigator)|
|Cardioprotection against Endotoxins||R Mestril||NIH/NHLBI||To study the mechanism by which hsp70 protects cardiomyocytes against endotoxin-induced injury.|
|Mechanical Activity and Myocyte Remodeling||AM Samarel
|NIH/NHLBI||To investigate the role of focal adhesion proteins and costameric components in cardiomyocyte remodeling in response to linear and transverse stretch. (subcontract with the University of Illinois at Chicago, a component of a P01 (Integrated mechanisms of cardiac maladaptation) for which Dr. John Solaro is principal investigator and Dr. Brenda Russell is project leader)|
|T3 Rx During Post-infarction LV Remodeling||AM Samarel
|T3 Therapeutics and King Pharmaceuticals||To develop a post-myocardial infarction model to facilitate study of the use of T3 in the treatment of congestive heart failure.|
|HIT Registry||JM Walenga
|Mitsubishi Pharmaceuticals||To create and maintain the Loyola Registry of Heparin-Induced Thrombocytopenia (HIT) in Cardiovascular Surgery Patients, the only available database of its kind in existence.|
|PiCT Evaluation||JM Walenga
|Pentapharm||To compare the performance of Pefakit PiCT (Pentapharm) to Heptest (Haemachem).|
|Differentiation of LMWHs||JM Walenga
|Sanofi-Aventis||Pharmacologic characterization and differentiation of low molecular weight heparins and heparin-derived oligosaccharides.|